International Stem Cell Corp. (ISCO) Announces Successful Intracranial Cell Transplantation in Phase I Clinical Study of ISC-hpNSC
Before the opening bell, International Stem Cell Corp. (OTCQB: ISCO) announced that the first patient in its ongoing phase I clinical trial of human parthenogenetic neural stem cells (ISC-hpNSC) for the treatment of moderate to severe Parkinson’s disease has undergone a successful intracranial transplant of ISC-hpNSC at the Royal Melbourne Hospital in Australia. This milestone marks a major step toward the completion of the dose escalation safety and preliminary efficacy study, which will evaluate three different dose regimens of ISC-hpNSC in a total of 12 participants over the coming months. “This is a major step forward in our search for…